Bufuralol Hydrochloride: Advanced Applications in β-Adrenergic Signaling and Organoid-Based Pharmacokinetics

Introduction

β-Adrenergic receptor antagonists, particularly non-selective agents with partial intrinsic sympathomimetic activity, have long served as foundational tools in cardiovascular pharmacology research. Bufuralol hydrochloride (CAS 60398-91-6), distinguished by its broad interaction with beta-adrenoceptors and unique membrane-stabilizing properties, offers significant advantages for dissecting the complexities of beta-adrenoceptor signaling pathways. Recent advances in human stem cell-derived organoid technology now enable more physiologically relevant in vitro pharmacokinetic studies, prompting a reassessment of how classical agents like Bufuralol hydrochloride can be integrated into these innovative models.

Bufuralol Hydrochloride: Chemical and Pharmacological Profile

Bufuralol hydrochloride is a crystalline small molecule with a molecular weight of 297.8 and the chemical formula C₁₆H₂₃NO₂·HCl. It is soluble up to 15 mg/ml in ethanol, 10 mg/ml in DMSO, and 15 mg/ml in dimethyl formamide, and requires storage at -20°C to maintain chemical stability. As a non-selective β-adrenergic receptor antagonist, Bufuralol hydrochloride exhibits partial intrinsic sympathomimetic activity, evidenced by its ability to induce tachycardia in animal models with depleted catecholamine stores. Additionally, its membrane-stabilizing effects have been demonstrated in vitro. In clinical pharmacology, Bufuralol hydrochloride provides prolonged inhibition of exercise-induced heart rate elevation, paralleling the effects of propranolol but with distinctive pharmacodynamic nuances. These properties position Bufuralol hydrochloride as a valuable instrument for both basic and translational β-adrenergic modulation studies.

Integration with Organoid-Based Pharmacokinetic Models

Traditional in vitro and in vivo models in cardiovascular pharmacology and drug metabolism research, such as the Caco-2 cell line and animal studies, are limited by species-specific differences and incomplete recapitulation of human physiological complexity. The emergence of human pluripotent stem cell-derived intestinal organoids (hiPSC-IOs) represents a significant methodological advancement (Saito et al., 2025). These three-dimensional structures recapitulate the cellular heterogeneity, transporter expression, and drug-metabolizing enzyme activity of the human intestinal epithelium, providing a more accurate platform for evaluating absorption, metabolism, and excretion of pharmacological agents.

In particular, hiPSC-IOs express key cytochrome P450 enzymes, such as CYP3A4, and transporter proteins like P-glycoprotein (P-gp), both of which are essential for the pharmacokinetic profiling of β-adrenergic receptor blockers. The utility of Bufuralol hydrochloride in this context is twofold: it serves as a probe substrate for CYP2D6 and CYP3A4 activity, and as a functional modulator in studies investigating β-adrenergic receptor signaling within organoid systems. These capabilities enable robust characterization of drug-drug interactions, metabolic clearance rates, and receptor-mediated physiological responses.

Applications in β-Adrenergic Modulation and Cardiovascular Disease Research

The non-selective profile of Bufuralol hydrochloride allows for comprehensive interrogation of both β₁ and β₂ adrenoceptor functions. Its partial intrinsic sympathomimetic activity distinguishes it from pure antagonists, providing nuanced modulation of adrenergic tone in cardiovascular tissues. In tachycardia animal models, Bufuralol hydrochloride demonstrates the capacity to induce heart rate elevation under conditions of catecholamine depletion, offering a unique lens on receptor reserve and downstream signaling mechanisms.

These features are particularly valuable in cardiovascular disease research, where the pathophysiological roles of β-adrenergic signaling are multifaceted. Bufuralol hydrochloride has been employed for dissecting the impact of chronic β-adrenergic blockade on cardiac remodeling, arrhythmogenesis, and stress-induced hypertrophy. Furthermore, its membrane-stabilizing properties have implications for arrhythmic risk modulation, complementing its hemodynamic effects. These aspects make it a central tool for both mechanistic and preclinical studies targeting beta-adrenoceptor pathways.

Methodological Considerations for Organoid-Based Studies

Utilizing Bufuralol hydrochloride in organoid-based systems requires attention to technical variables that can influence experimental outcomes. Given its solubility profile, researchers should select solvents compatible with both the compound and the organoid matrix (such as ethanol or DMSO at concentrations non-toxic to cells), and prepare working solutions immediately prior to use to avoid degradation. Storage at -20°C is essential for maintaining compound integrity, and long-term storage of prepared solutions should be avoided as per manufacturer recommendations.

When integrating Bufuralol hydrochloride into hiPSC-derived intestinal organoids, dosing paradigms must account for its rapid metabolism by CYP2D6 and CYP3A4 enzymes. Time-course sampling and analytical quantification using validated LC-MS/MS protocols are recommended for accurate assessment of metabolic turnover and pharmacokinetic parameters. The ability of organoid models to recapitulate human-specific transporter and enzyme expression enables direct comparison with in vivo human data, overcoming limitations observed in animal models or immortalized cell lines.

Expanding the Utility of Bufuralol Hydrochloride in Complex Co-Culture Systems

Beyond intestinal organoids, the application of Bufuralol hydrochloride extends to multi-tissue co-culture platforms—such as heart-intestine or liver-intestine organoid assemblies—designed to mimic systemic pharmacokinetics and cardiodynamic interactions. These systems facilitate the study of first-pass metabolism, inter-organ signaling, and the impact of β-adrenergic modulation on barrier function and systemic drug disposition. By leveraging the partial agonist profile of Bufuralol hydrochloride, researchers can interrogate compensatory pathways and receptor desensitization phenomena in a controlled, human-relevant context.

For instance, studies employing microfluidic devices or "organ-on-chip" platforms can utilize Bufuralol hydrochloride to examine the interplay between intestinal absorption, hepatic metabolism, and cardiac β-adrenergic responses in real time. This approach enables detailed mechanistic dissection of pharmacokinetic-pharmacodynamic (PK-PD) relationships, supporting rational drug design and safety assessment in preclinical pipelines.

Comparative Insights and Interlinking with Existing Research

While previous reviews have discussed the role of Bufuralol hydrochloride in modulation of β-adrenergic signaling, such as in the article "Bufuralol Hydrochloride in β-Adrenergic Modulation: Insights and Applications", the present article offers additional depth by focusing on the integration of Bufuralol hydrochloride into advanced organoid and multi-organ culture systems. Unlike prior works that emphasize isolated pharmacodynamic effects or traditional cell line-based approaches, this review provides practical guidance for leveraging hiPSC-derived organoids and co-culture platforms to address longstanding challenges in β-adrenergic modulation studies and cardiovascular disease research. In doing so, it extends the experimental toolkit available to researchers and highlights the translational potential of combining classic pharmacological agents with cutting-edge in vitro technologies.

Conclusion

Bufuralol hydrochloride remains a critical agent in the elucidation of beta-adrenoceptor signaling pathways and cardiovascular pharmacology. Its unique profile as a non-selective β-adrenergic receptor blocker with partial intrinsic sympathomimetic activity, combined with membrane-stabilizing effects, offers multifaceted utility for both basic and translational research. The convergence of this classic pharmacological tool with state-of-the-art organoid technologies, as demonstrated in recent studies (Saito et al., 2025), is poised to accelerate advances in pharmacokinetic modeling, drug discovery, and cardiovascular disease research. By strategically integrating Bufuralol hydrochloride into organoid-based and multi-tissue platforms, investigators can achieve unprecedented resolution in dissecting human-relevant β-adrenergic modulation and its implications for health and disease.